<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00306319</url>
  </required_header>
  <id_info>
    <org_study_id>UMCN-AKF 05.02</org_study_id>
    <secondary_id>Primo study</secondary_id>
    <nct_id>NCT00306319</nct_id>
  </id_info>
  <brief_title>Pharmacokinetic Interaction Study in Indonesian Tuberculosis Patients Indonesia</brief_title>
  <official_title>Pharmacokinetic Interaction Study of Rifampicin, Isoniazid and Moxifloxacin in Tuberculosis Patients in Bandung, Indonesia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Radboud University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Radboud University</source>
  <brief_summary>
    <textblock>
      Pharmacokinetic study in TB patients to determine the effect of rifampicin on the&#xD;
      pharmacokinetic profile of moxifloxacin.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Tuberculosis is an infectious disease that still causes many victims in the developing world,&#xD;
      especially in Indonesia. Rifampicin, isoniazid and ethambutol are the cornerstone of the&#xD;
      current treatment. The disadvantage of the current treatment is the long, six-months,&#xD;
      duration of the treatment. This long duration contributes to suboptimal adherence to the TB&#xD;
      drugs.Thus, there is a very urgent need to evaluate drugs that may help shortening TB&#xD;
      treatment. The fluoroquinolone moxifloxacin has shown early bactericidal activity (EBA) in&#xD;
      patients with pulmonary TB, and has shown rapid and reliable sterilization. Rifampicin is a&#xD;
      strong inducer of the CYP enzymes, but it also induces phase II metabolism. As moxifloxacin&#xD;
      is metabolized by phase II metabolism, rifampicin could cause a decrease in the plasma&#xD;
      concentrations of moxifloxacin. Therefore, a pharmacokinetic interaction study is warranted.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2006</start_date>
  <completion_date type="Actual">May 2006</completion_date>
  <primary_completion_date type="Actual">May 2006</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pharmacokinetic (24 hrs) curves will be drawn</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>at day 5 in period I and period II.</measure>
  </primary_outcome>
  <enrollment>23</enrollment>
  <condition>Tuberculosis</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>moxifloxacin</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Indonesian AFB negative tuberculosis patients who are in the last two months of the&#xD;
             continuation phase of their six-month-antituberculosis treatment.&#xD;
&#xD;
          -  Subject is 18-55 years of age at the day of the first dosing of study medication.&#xD;
&#xD;
          -  Subject has a normal ECG&#xD;
&#xD;
          -  Subjects bodyweight is &gt;35kg&#xD;
&#xD;
          -  Use of rifampicin and isoniazid&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnant or lactating&#xD;
&#xD;
          -  History or condition that might interfere with drug absorption, distribution,&#xD;
             metabolism or excretion, including ileus, gastric paresis, liver and renal&#xD;
             dysfunction, diabetes mellitus.&#xD;
&#xD;
          -  Presence of contraindications for moxifloxacin or use of drugs that are known to&#xD;
             interact with moxifloxacin.&#xD;
&#xD;
          -  Subject is not able and/or not willing to sign the informed consent form.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>R. Aarnoutse, PharmD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Radboud University (RUNMC)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Rumah Sakit Hasan Sadikin (RSHS)</name>
      <address>
        <city>Bandung</city>
        <country>Indonesia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Indonesia</country>
  </location_countries>
  <results_reference>
    <citation>Nijland HM, Ruslami R, Suroto AJ, Burger DM, Alisjahbana B, van Crevel R, Aarnoutse RE. Rifampicin reduces plasma concentrations of moxifloxacin in patients with tuberculosis. Clin Infect Dis. 2007 Oct 15;45(8):1001-7. Epub 2007 Sep 4.</citation>
    <PMID>17879915</PMID>
  </results_reference>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>March 22, 2006</study_first_submitted>
  <study_first_submitted_qc>March 22, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 23, 2006</study_first_posted>
  <last_update_submitted>November 9, 2020</last_update_submitted>
  <last_update_submitted_qc>November 9, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 12, 2020</last_update_posted>
  <keyword>Tuberculosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tuberculosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Moxifloxacin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

